Medicenna Therapeutics Corp.

Toronto Stock Exchange MDNA.TO

Medicenna Therapeutics Corp. Gross Profit for the year ending March 31, 2024: USD -3.69 K

Medicenna Therapeutics Corp. Gross Profit is USD -3.69 K for the year ending March 31, 2024, a 0.16% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.
  • Medicenna Therapeutics Corp. Gross Profit for the year ending March 31, 2023 was USD -3.70 K, a 87.83% change year over year.
  • Medicenna Therapeutics Corp. Gross Profit for the year ending March 31, 2022 was USD -30.37 K, a 4.60% change year over year.
  • Medicenna Therapeutics Corp. Gross Profit for the year ending March 31, 2021 was USD -31.83 K, a -467.59% change year over year.
  • Medicenna Therapeutics Corp. Gross Profit for the year ending March 31, 2020 was USD -5.61 K, a -9.78% change year over year.
Key data
Date Gross Profit Operating Income EBIT EBITDA
Market news
SV Wall Street
Toronto Stock Exchange: MDNA.TO

Medicenna Therapeutics Corp.

CEO Dr. Fahar Merchant Ph.D.
IPO Date March 8, 2017
Location Canada
Headquarters 2 Bloor Street West
Employees 16
Sector Healthcare
Industries
Biotechnology Pharmaceuticals Vaccines
Description

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Similar companies

ONC.TO

Oncolytics Biotech Inc.

USD 0.73

3.09%

StockViz Staff

February 6, 2025

Any question? Send us an email